Print this page
-
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer.
Protocol: 001502Principal Investigator:
-
Gregory Riedlinger
Applicable Disease Sites: Any Site -
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Applicable Disease Sites: Liver
-
Evolution and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in Breast Tumor Microenvironment.
Protocol: 001839Principal Investigator:
-
Shridar Ganesan
Applicable Disease Sites: Breast -
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
HPV Vaccine Hesitancy in Low Uptake Communities.
Protocol: 002064Principal Investigator:
-
Racquel Kohler
Applicable Disease Sites: Cervix -
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
-
Malcolm Mattes
Applicable Disease Sites: Any Site -
Cutaneous Oncology Clinical Database and Biospecimen Bank
Protocol: 002233Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
AYA Cancer Survivor and Parent Communication and Transition Readiness
Protocol: 002308Applicable Disease Sites: Any Site
-
Therapy and Outcome Prediction using Urothelial Carcinoma orgANoids (TOUCAN)
Protocol: 002425Principal Investigator:
-
Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.
Protocol: 012103Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Starting Second- or Third-line Therapy and not Receiving Autologous Stem Cell Transplant.
Protocol: 012104Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
-
Ira Braunschweig
Applicable Disease Sites: Multiple Myeloma -
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.
Protocol: 012207Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Any Site